Epidemiological survival predictors of cancer of the corpus uteri: a population-based analysis

Cancer of the corpus uteri (CCU) is one of the most common gynecological malignancies in high- and middleincome countries. The objective of the study was to evaluate the factors predicting survival in CCU patients over the period 2000-2021 using the data of population-based cancer registry of the Arkhangelsk region. Material and Methods. Cancer-specific survival (CSS) of patients with CCU for the period 2000-21 was evaluated using life tables and Kaplan-Mayer methods with a log-rank test. The Cox proportional hazards regression model was used to assess the effect of prognostic factors on survival time. Results. A total of 3272 cases were selected for the analysis. The 5-year survival rates improved from 70.6 % in 2000-04 to 75.6 % in 2015-19. In stage I, II, III, and IV CUN, the 5-year survival rates were 90.8 % (95 % CI 89.3-92.0 %), 71.1 (95 % CI 66.3-75.4 %), 46.7 (95 % CI 41.4-51.8 %), and 3.9 (95 % CI 1.5-7.5 %), respectively; p<0.001. In the multivariate regression model, for stage II, III, and IV CCU, the hazard ratios for death from cancer were respectively 2.69 (2.14-3.39), 5.73 (4.66-7.03), and 20.26 (16.13-25.44) compared to stage I. The risk of death from CCU was 2.0-2.7 times higher in patients with aggressive histological subtypes and sarcomas compared to that in patients with endometrioid adenocarcinoma; 2.0-2.8 times higher in patients older than 60 years compared to younger patients, and 1.3 times higher in rural patients compared to urban patients (p<0.05). There was no increase in the risk of death from CCU over the period of COVID-19 pandemic. Conclusion. In this population-based study, we have found that the survival of patients with CCU is significantly affected by age and place of residence, which may indicate a limited access of some patients to effective treatment and requires further analysis. No increased risk of death from CCU during the COVID-19 pandemic was found.

1. Global cancer observatory. Cancer today [Internet]. [cited 2023 Jan 20]. URL: https://gco.iarc.fr/today/.

2. Malignant tumors in Russia in 2020 (morbidity and mortality). Ed. by A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova. Moscow, 2021. 252 p. (in Russian).

3. Sant M., Chirlaque Lopez M.D., Agresti R., Sánchez Pérez M.J., Holleczek B., Bielska-Lasota M., Dimitrova N., Innos K., Katalinic A., Langseth H., Larrañaga N., Rossi S., Siesling S., Minicozzi P.; EUROCARE-5 Working Group. Survival of women with cancers of breast and genital organs in Europe 1999-2007: Results of the EUROCARE-5 study. Eur J Cancer. 2015; 51(15): 2191-2205. doi: 10.1016/j.ejca.2015.07.022.

4. Wortman B.G., Creutzberg C.L., Putter H., Jurgeriliemk-Schulz IM., Jobsen J.J., Lutgens L.C.H.W., van der Steen-Banasik E.M., Mens J.W.M., Slot A., Kroese M.C.S., van Triest B., Nijman H.W., Stelloo E., Bosse T., de Boer S.M., van Putten W.L.J., Smit V.T.H.B.M., Nout R.A.; PORTEC Study Group. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. Br J Cancer. 2018; 119(9): 1067-74. doi: 10.1038/s41416-018-0310-8.

5. Coleman M.P. Cancer survival: global surveillance will stimulate health policy and improve equity. Lancet. 2014; 383(9916): 564-73. doi: 10.1016/S0140-6736(13)62225-4.

6. Valkov M.Yu., Kar-punov A.A., Coleman M.P., Allemani K., Pankratieva A.Yu., Potekhina E.F., Valkova L.E., Grjibovski A.M. The population-based cancer registry as a resource for research and practical healthcare. Ecology of Man. 2017; (5): 54-62. (in Russian).

7. Koskas M., Amant F., Mirza M.R., Creutzberg C.L. Cancer of the corpus uteri: 2021 update. Int J Gynaecol Obstet. 2021; 155 (s1): 45-60. doi: 10.1002/ijgo.13866.

8. Ojamaa K., Veerus P., Baburin A., Everaus H., Innos K. Increasing incidence and survival of corpus uteri cancer in Estonia over the past two decades. Cancer Epidemiol. 2019; 62. doi: 10.1016/j.canep.2019.101566.

9. Valkova L.E., Merabishvili V.M., Pankratieva A.Yu., Agaeva A.V., Ryzhov A.Yu., Potekhina E.F., Shcherbakov A.M., Dyachenko A.A., Voroshilov Yu.A., Valkov M.Yu. Survival of cancer patients screened at the first stage of dispanserization of certain groups of the adult population: a populationbased epidemiological analysis. Problems in Oncology. 2021; 67(4): 501-10. (in Russian). doi: 10.37469/0507-3758-2021-67-4-501-510.

10. Manchanda R., Oxley S., Ghaem-Maghami S., Sundar S. COVID-19 and the impact on gynecologic cancer care. Int J Gynaecol Obstet. 2021; 155(1): 94-101. doi: 10.1002/ijgo.13868.

11. Blackburn B.E., Soisson S., Rowe K., Snyder J., Fraser A., Deshmukh V., Newman M., Smith K., Herget K., Kirchhoff A.C., Kepka D., Werner T.L., Gaffney D., Mooney K., Hashibe M. Prognostic factors for rural endometrial cancer patients in a population-based cohort. BMC Public Health. 2019; 19(1); 921. doi: 10.1186/s12889-019-7262-7.

12. Merabishvili V.M. Malignant tumors in the North-West Federal Region of Russia (morbidity, mortality, index accuracy, survival). Fifth issue. St. Petersburg, 2020. 104 p. (in Russian).